Hosted on MSN

Could Your Nose Picking Habit Raise Alzheimer's Risk? New Research Explores a Surprising Link

New research suggests a surprising and potentially concerning link between a common habit—picking your nose—and the risk of developing Alzheimer’s disease. A study published in 2022 revealed a tenuous ...
Hosted on MSN

Mouse study suggests nose-picking has a surprising link with Alzheimer's

A study published in 2022 found a tenuous but plausible link between picking your nose and an increased risk of developing dementia. In cases where picking at your nose causes internal tissue damage, ...
Healio

FDA approves second Niemann-Pick disease type C treatment

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Aqneursa as an oral treatment for neurological symptoms associated with Niemann-Pick ...
Nasdaq

Zevra Launches Niemann-Pick Disease Type C Drug Miplyffa In The U.S.

(RTTNews) - Zevra Therapeutics Inc. (ZVRA), a rare disease therapeutics company, Thursday, announced the commercial availability of Miplyffa for the treatment of Niemann-Pick disease type C along with ...
Seeking Alpha

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global Niemann-Pick ...
Healio

Miplyffa commercially available for treatment of Niemann-Pick disease type C

Please provide your email address to receive an email when new articles are posted on . Zevra Therapeutics has announced that Miplyffa, the first Nieman-Pick disease type C treatment approved by the ...
FiercePharma

After winning historic nod, Zevra CCO expects new drug Miplyffa to become 'cornerstone' of Niemann-Pick treatment

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C (NPC) community, Zevra Therapeutics is confident that its new drug Miplyffa ...
Morningstar

Mandos Health to Present New Analyses in Niemann-Pick Disease Type C at the 2025 American Neurological Association Annual Meeting

Mandos Health® by Beren Therapeutics Public Benefit Corporation (P.B.C.) announced today that new analyses detailing the clinical and biological effects of its investigational drug, adrabetadex, in ...
Pharmabiz

IntraBio’s Aqneursa receives European Commission’s marketing approval for treatment of Niemann-Pick Type C disease

IntraBio’s Aqneursa receives European Commission’s marketing approval for treatment of Niemann-Pick Type C disease: Austin, Texas Saturday, January 24, 2026, 14:00 Hrs [IST] I ...
Morningstar

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros’ mission to develop treatments for the ...
Monthly Prescribing Reference

FDA Approves Aqneursa for Niemann-Pick Disease Type C

The recommended dosage is based on the patient’s body weight. The Food and Drug Administration (FDA) has approved Aqneursa ™ (levacetylleucine) for the treatment of neurological manifestations of ...